<SEC-DOCUMENT>0001415889-25-002471.txt : 20250131
<SEC-HEADER>0001415889-25-002471.hdr.sgml : 20250131
<ACCEPTANCE-DATETIME>20250131161530
ACCESSION NUMBER:		0001415889-25-002471
CONFORMED SUBMISSION TYPE:	SCHEDULE 13D/A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250131
DATE AS OF CHANGE:		20250131

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Repare Therapeutics Inc.
		CENTRAL INDEX KEY:			0001808158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			Z4
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-91542
		FILM NUMBER:		25578566

	BUSINESS ADDRESS:	
		STREET 1:		7171 FREDERICK BANTING
		STREET 2:		SUITE 270, BUILDING 2
		CITY:			SAINT-LAURENT
		STATE:			A8
		ZIP:			H4S 1Z9
		BUSINESS PHONE:		(857) 412-7018

	MAIL ADDRESS:	
		STREET 1:		7171 FREDERICK BANTING
		STREET 2:		SUITE 270, BUILDING 2
		CITY:			SAINT-LAURENT
		STATE:			A8
		ZIP:			H4S 1Z9

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MPM BioVentures 2014, L.P.
		CENTRAL INDEX KEY:			0001609492
		ORGANIZATION NAME:           	
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A

	BUSINESS ADDRESS:	
		STREET 1:		C/O MPM BIOIMPACT
		STREET 2:		399 BOYLSTON STREET, SUITE 1100
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
		BUSINESS PHONE:		(617) 425-9200

	MAIL ADDRESS:	
		STREET 1:		C/O MPM BIOIMPACT
		STREET 2:		399 BOYLSTON STREET, SUITE 1100
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13D/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13D" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13D/A</submissionType>
		<previousAccessionNumber>0001193125-21-328063</previousAccessionNumber>
	    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001609492</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>





    </filerInfo>
  </headerData>

  <formData>
    <coverPageHeader>
		<amendmentNo>7</amendmentNo>
	      <securitiesClassTitle>Common Shares</securitiesClassTitle>
      <dateOfEvent>01/31/2025</dateOfEvent>
	  <previouslyFiledFlag>false</previouslyFiledFlag>
      <issuerInfo>
        <issuerCIK>0001808158</issuerCIK>
        <issuerCUSIP>760273102</issuerCUSIP>
		<issuerName>REPARE THERAPEUTICS INC.</issuerName>

        <address>
          <com:street1>7171 FREDERICK BANTING</com:street1>
          <com:street2>SUITE 270, BUILDING 2</com:street2>          <com:city>SAINT-LAURENT</com:city>
          <com:stateOrCountry>A8</com:stateOrCountry>
          <com:zipCode>H4S 1Z9</com:zipCode>
        </address>
      </issuerInfo>

	  	  <authorizedPersons>

		<notificationInfo>
			<personName>Ansbert Gadicke</personName>
			<personPhoneNum>617-425-9200</personPhoneNum>
				<personAddress>
					<com:street1>c/o MPM BioImpact LLC</com:street1>
					<com:street2>339 Boylston Street, Suite 1100</com:street2>					<com:city>Boston</com:city>
					<com:stateOrCountry>MA</com:stateOrCountry>
					<com:zipCode>02116</com:zipCode>
				</personAddress>
		</notificationInfo>
			</authorizedPersons>
	    </coverPageHeader>

	<reportingPersons>


			<reportingPersonInfo>
									<reportingPersonCIK>0001609492</reportingPersonCIK>

				<reportingPersonNoCIK>N</reportingPersonNoCIK>
				<reportingPersonName>MPM BioVentures 2014, L.P. </reportingPersonName>

								<memberOfGroup>b</memberOfGroup>





				  				  <fundType>WC</fundType>



				<legalProceedings>N</legalProceedings>

								<citizenshipOrOrganization>DE</citizenshipOrOrganization>
												<soleVotingPower>1018345.00</soleVotingPower>
												<sharedVotingPower>0.00</sharedVotingPower>
												<soleDispositivePower>1018345.00</soleDispositivePower>

				<sharedDispositivePower>0.00</sharedDispositivePower>
												<aggregateAmountOwned>1018345.00</aggregateAmountOwned>

				<isAggregateExcludeShares>N</isAggregateExcludeShares>

								<percentOfClass>2.4</percentOfClass>






			  			  <typeOfReportingPerson>PN</typeOfReportingPerson>









			</reportingPersonInfo>

			<reportingPersonInfo>
									<reportingPersonCIK>0001609493</reportingPersonCIK>

				<reportingPersonNoCIK>N</reportingPersonNoCIK>
				<reportingPersonName>MPM BioVentures 2014 (B), L.P. </reportingPersonName>

								<memberOfGroup>b</memberOfGroup>





				  				  <fundType>WC</fundType>



				<legalProceedings>N</legalProceedings>

								<citizenshipOrOrganization>DE</citizenshipOrOrganization>
												<soleVotingPower>67921.00</soleVotingPower>
												<sharedVotingPower>0.00</sharedVotingPower>
												<soleDispositivePower>67921.00</soleDispositivePower>

				<sharedDispositivePower>0.00</sharedDispositivePower>
												<aggregateAmountOwned>67921.00</aggregateAmountOwned>

				<isAggregateExcludeShares>N</isAggregateExcludeShares>

								<percentOfClass>0.2</percentOfClass>






			  			  <typeOfReportingPerson>PN</typeOfReportingPerson>









			</reportingPersonInfo>

			<reportingPersonInfo>
									<reportingPersonCIK>0001609495</reportingPersonCIK>

				<reportingPersonNoCIK>N</reportingPersonNoCIK>
				<reportingPersonName>MPM Asset Management Investors BV2014 LLC </reportingPersonName>

								<memberOfGroup>b</memberOfGroup>





				  				  <fundType>WC</fundType>



				<legalProceedings>N</legalProceedings>

								<citizenshipOrOrganization>DE</citizenshipOrOrganization>
												<soleVotingPower>35052.00</soleVotingPower>
												<sharedVotingPower>0.00</sharedVotingPower>
												<soleDispositivePower>35052.00</soleDispositivePower>

				<sharedDispositivePower>0.00</sharedDispositivePower>
												<aggregateAmountOwned>35052.00</aggregateAmountOwned>

				<isAggregateExcludeShares>N</isAggregateExcludeShares>

								<percentOfClass>0.1</percentOfClass>












			  			  <typeOfReportingPerson>OO</typeOfReportingPerson>



			</reportingPersonInfo>

			<reportingPersonInfo>
									<reportingPersonCIK>0001691428</reportingPersonCIK>

				<reportingPersonNoCIK>N</reportingPersonNoCIK>
				<reportingPersonName>UBS Oncology Impact Fund L.P. </reportingPersonName>

								<memberOfGroup>b</memberOfGroup>





				  				  <fundType>WC</fundType>



				<legalProceedings>N</legalProceedings>

								<citizenshipOrOrganization>E9</citizenshipOrOrganization>
												<soleVotingPower>819924.00</soleVotingPower>
												<sharedVotingPower>0.00</sharedVotingPower>
												<soleDispositivePower>819924.00</soleDispositivePower>

				<sharedDispositivePower>0.00</sharedDispositivePower>
												<aggregateAmountOwned>819924.00</aggregateAmountOwned>

				<isAggregateExcludeShares>N</isAggregateExcludeShares>

								<percentOfClass>1.9</percentOfClass>






			  			  <typeOfReportingPerson>PN</typeOfReportingPerson>









			</reportingPersonInfo>

			<reportingPersonInfo>
									<reportingPersonCIK>0001765091</reportingPersonCIK>

				<reportingPersonNoCIK>N</reportingPersonNoCIK>
				<reportingPersonName>MPM BioVentures 2014 GP LLC </reportingPersonName>

								<memberOfGroup>b</memberOfGroup>





				  				  <fundType>WC</fundType>



				<legalProceedings>N</legalProceedings>

								<citizenshipOrOrganization>DE</citizenshipOrOrganization>
												<soleVotingPower>0.00</soleVotingPower>
												<sharedVotingPower>1086266.00</sharedVotingPower>
												<soleDispositivePower>0.00</soleDispositivePower>

				<sharedDispositivePower>1086266.00</sharedDispositivePower>
												<aggregateAmountOwned>1086266.00</aggregateAmountOwned>

				<isAggregateExcludeShares>N</isAggregateExcludeShares>

								<percentOfClass>2.6</percentOfClass>












			  			  <typeOfReportingPerson>OO</typeOfReportingPerson>



			</reportingPersonInfo>

			<reportingPersonInfo>
									<reportingPersonCIK>0001765021</reportingPersonCIK>

				<reportingPersonNoCIK>N</reportingPersonNoCIK>
				<reportingPersonName>MPM BioVentures 2014 LLC </reportingPersonName>

								<memberOfGroup>b</memberOfGroup>





				  				  <fundType>WC</fundType>



				<legalProceedings>N</legalProceedings>

								<citizenshipOrOrganization>DE</citizenshipOrOrganization>
												<soleVotingPower>0.00</soleVotingPower>
												<sharedVotingPower>1121318.00</sharedVotingPower>
												<soleDispositivePower>0.00</soleDispositivePower>

				<sharedDispositivePower>1121318.00</sharedDispositivePower>
												<aggregateAmountOwned>1121318.00</aggregateAmountOwned>

				<isAggregateExcludeShares>N</isAggregateExcludeShares>

								<percentOfClass>2.6</percentOfClass>












			  			  <typeOfReportingPerson>OO</typeOfReportingPerson>



			</reportingPersonInfo>

			<reportingPersonInfo>
									<reportingPersonCIK>0001721036</reportingPersonCIK>

				<reportingPersonNoCIK>N</reportingPersonNoCIK>
				<reportingPersonName>Oncology Impact Fund (Cayman) Management L.P. </reportingPersonName>

								<memberOfGroup>b</memberOfGroup>





				  				  <fundType>WC</fundType>



				<legalProceedings>N</legalProceedings>

								<citizenshipOrOrganization>E9</citizenshipOrOrganization>
												<soleVotingPower>0.00</soleVotingPower>
												<sharedVotingPower>819924.00</sharedVotingPower>
												<soleDispositivePower>0.00</soleDispositivePower>

				<sharedDispositivePower>819924.00</sharedDispositivePower>
												<aggregateAmountOwned>819924.00</aggregateAmountOwned>

				<isAggregateExcludeShares>N</isAggregateExcludeShares>

								<percentOfClass>1.9</percentOfClass>






			  			  <typeOfReportingPerson>PN</typeOfReportingPerson>









			</reportingPersonInfo>

			<reportingPersonInfo>
									<reportingPersonCIK>0001687078</reportingPersonCIK>

				<reportingPersonNoCIK>N</reportingPersonNoCIK>
				<reportingPersonName>MPM BioImpact LLC </reportingPersonName>

								<memberOfGroup>b</memberOfGroup>





				  				  <fundType>WC</fundType>



				<legalProceedings>N</legalProceedings>

								<citizenshipOrOrganization>DE</citizenshipOrOrganization>
												<soleVotingPower>0.00</soleVotingPower>
												<sharedVotingPower>819924.00</sharedVotingPower>
												<soleDispositivePower>0.00</soleDispositivePower>

				<sharedDispositivePower>819924.00</sharedDispositivePower>
												<aggregateAmountOwned>819924.00</aggregateAmountOwned>

				<isAggregateExcludeShares>N</isAggregateExcludeShares>

								<percentOfClass>1.9</percentOfClass>












			  			  <typeOfReportingPerson>OO</typeOfReportingPerson>



			</reportingPersonInfo>

			<reportingPersonInfo>
									<reportingPersonCIK>0001134655</reportingPersonCIK>

				<reportingPersonNoCIK>N</reportingPersonNoCIK>
				<reportingPersonName>ANSBERT GADICKE</reportingPersonName>

								<memberOfGroup>b</memberOfGroup>





				  				  <fundType>WC</fundType>



				<legalProceedings>N</legalProceedings>

								<citizenshipOrOrganization>X1</citizenshipOrOrganization>
												<soleVotingPower>0.00</soleVotingPower>
												<sharedVotingPower>1941242.00</sharedVotingPower>
												<soleDispositivePower>0.00</soleDispositivePower>

				<sharedDispositivePower>1941242.00</sharedDispositivePower>
												<aggregateAmountOwned>1941242.00</aggregateAmountOwned>

				<isAggregateExcludeShares>N</isAggregateExcludeShares>

								<percentOfClass>4.6</percentOfClass>











			  			  <typeOfReportingPerson>IN</typeOfReportingPerson>




			</reportingPersonInfo>

			<reportingPersonInfo>
									<reportingPersonCIK>0001134657</reportingPersonCIK>

				<reportingPersonNoCIK>N</reportingPersonNoCIK>
				<reportingPersonName>LUKE EVNIN</reportingPersonName>

								<memberOfGroup>b</memberOfGroup>





				  				  <fundType>WC</fundType>



				<legalProceedings>N</legalProceedings>

								<citizenshipOrOrganization>X1</citizenshipOrOrganization>
												<soleVotingPower>0.00</soleVotingPower>
												<sharedVotingPower>1121318.00</sharedVotingPower>
												<soleDispositivePower>0.00</soleDispositivePower>

				<sharedDispositivePower>1121318.00</sharedDispositivePower>
												<aggregateAmountOwned>1121318.00</aggregateAmountOwned>

				<isAggregateExcludeShares>N</isAggregateExcludeShares>

								<percentOfClass>2.6</percentOfClass>











			  			  <typeOfReportingPerson>IN</typeOfReportingPerson>




			</reportingPersonInfo>

			<reportingPersonInfo>
									<reportingPersonCIK>0001473930</reportingPersonCIK>

				<reportingPersonNoCIK>N</reportingPersonNoCIK>
				<reportingPersonName>Todd Foley</reportingPersonName>

								<memberOfGroup>b</memberOfGroup>





				  				  <fundType>WC</fundType>



				<legalProceedings>N</legalProceedings>

								<citizenshipOrOrganization>X1</citizenshipOrOrganization>
												<soleVotingPower>0.00</soleVotingPower>
												<sharedVotingPower>1121318.00</sharedVotingPower>
												<soleDispositivePower>0.00</soleDispositivePower>

				<sharedDispositivePower>1121318.00</sharedDispositivePower>
												<aggregateAmountOwned>1121318.00</aggregateAmountOwned>

				<isAggregateExcludeShares>N</isAggregateExcludeShares>

								<percentOfClass>2.6</percentOfClass>











			  			  <typeOfReportingPerson>IN</typeOfReportingPerson>




			</reportingPersonInfo>
			</reportingPersons>


	<items1To7>
		<item1>
			<securityTitle>Common Shares</securityTitle>
			<issuerName>REPARE THERAPEUTICS INC.</issuerName>

			<issuerPrincipalAddress>
			 <com:street1>7171 FREDERICK BANTING</com:street1>
			  <com:street2>SUITE 270, BUILDING 2</com:street2>			  <com:city>SAINT-LAURENT</com:city>
			  <com:stateOrCountry>A8</com:stateOrCountry>
			  <com:zipCode>H4S 1Z9</com:zipCode>
			</issuerPrincipalAddress>

						<commentText>Explanatory Note:  This Amendment No. 7 to Schedule 13D ('Amendment No. 7') is being filed as an amendment to the initial statement on Schedule 13D relating to the common shares (the 'Common Shares'), of Repare Therapeutics Inc. (the 'Issuer'), as filed with the Securities and Exchange Commission (the 'SEC') on July 6, 2020, as amended by Amendment No. 1 filed March 23, 2021, Amendment No. 2 filed May 25, 2021, Amendment No. 3 filed July 21, 2021, Amendment No. 4 filed December 26, 2024, Amendment No. 5 filed January 6, 2025 and Amendment No. 6 filed January 15, 2025 (as amended, the 'Original Schedule 13D').   This Schedule 13D/A is being filed by the Filing Persons to report the open market sales of the Issuer's Common Shares by certain Filing Persons.

Items 5 and 7 of the Original Schedule 13D are hereby amended and supplemented to the extent hereinafter expressly set forth and, except as amended and supplemented hereby, the Original Schedule 13D remains in full force and effect.  All capitalized terms used in this Amendment No. 7 but not defined herein shall have the meanings ascribed thereto in the Original Schedule 13D.
</commentText>
					</item1>




				<item5>
			 <percentageOfClassSecurities>See rows (11) and (13) of the Filing Persons Owner Profile of this Amendment No. 7 for the aggregate number of Common Shares and percentages of the shares of Common Shares beneficially owned by the Filing Person.

The Common Shares are held as follows:

*	1,018,345 shares are held directly by BV 2014;
*	67,921 shares are held directly by BV 2014(B);
*	35,052 shares are held directly by AM BV2014 LLC; and
*	819,924 shares are held directly by UBS Oncology.

BV 2014 GP and BV 2014 LLC are the direct and indirect general partners of BV 2014 and BV 2014(B) and, accordingly, may be deemed to beneficially own the shares held by BV 2014 and BV 2014(B).

BV 2014 LLC is the managing member of AM BV2014 LLC and, accordingly, may be deemed to beneficially own the shares held by AM BV2014 LLC.

BioImpact and Oncology Cayman are the direct and indirect general partners of UBS Oncology and, accordingly, may be deemed to beneficially own the shares held by UBS Oncology.

Drs. Gadicke and Evnin and Mr. Foley are the managing directors of BV 2014 LLC and, accordingly, may be deemed to beneficially own the shares held by BV 2014, BV 2014(B) and AM BV2014 LLC.

Dr. Gadicke is the managing partner of BioImpact and, accordingly may be deemed to beneficially own the shares held by UBS Oncology.

Calculation of the percentage of the shares of Common Shares beneficially owned is based upon 42,510,708 Common Shares outstanding as of November 1, 2024, as reported in the Issuer's Form 10-Q filed with the SEC on November 7, 2024.
</percentageOfClassSecurities>			<numberOfShares>See rows (7) through (10) of the Filing Persons Owner Profile of this Amendment No. 7 for the number of shares as to which there is sole power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or to direct the disposition.</numberOfShares>			<transactionDesc>The Filing Persons sold the following Common Shares in the open market since the date of filing Amendment No. 6:

Date of Sale Price Range  Ave. Price         Sold by        Sold by         Sold By AM BV           Sold by
                                                                   BV 2014   BV 2104(B)           2014 LLC           UBS Oncology
1/16/25           $1.255-$1.32       $1.27          10,326             689                   356                       8,314
1/17/25           $1.2599-$1.2901 $1.28          20,071          1,339                   690                     16,160
1/21/25           $1.22-$1.31         $1.24          16,024          1,069                   551                     12,902
1/22/25           $1.20-$1.235       $1.22          19,017          1,268                   655                     15,312
1/23/25           $1.155-$1.22       $1.20          21,705          1,448                   746                     17,476
1/24/25           $1.20-$1.26         $1.23           5,796              387                   199                       4,667
1/27/25           $1.15-$1.2034     $1.18          16,265          1,085                   560                     13,096</transactionDesc>			<listOfShareholders>Inapplicable.</listOfShareholders>			<date5PercentOwnership>All Filing Persons ceased to be the beneficial owners of more than five percent of the Common Shares on January 17, 2025.</date5PercentOwnership>		</item5>


				<item7>
			<filedExhibits>Joint Filing Statement</filedExhibits>
		</item7>

	</items1To7>

<signatureInfo>

	<signaturePerson>
		<signatureReportingPerson>MPM BioVentures 2014, L.P. </signatureReportingPerson>

					<signatureDetails>
				<signature>/s/ Ansbert Gadicke</signature>
				<title>Managing Director of MPM BioVentures 2014 LLC, the Managing Member of MPM BioVentures 2014 GP LLC, the General Partner of MPM BioVentures 2014, L.P.</title>
				<date>01/31/2025</date>
			</signatureDetails>

	</signaturePerson>

	<signaturePerson>
		<signatureReportingPerson>MPM BioVentures 2014 (B), L.P. </signatureReportingPerson>

					<signatureDetails>
				<signature>/s/ Ansbert Gadicke</signature>
				<title>Managing Director of MPM BioVentures 2014 LLC, Managing Member of MPM BioVentures 2014 GP LLC, the General Partner of MPM BioVentures 2014 (B), L.P</title>
				<date>01/31/2025</date>
			</signatureDetails>

	</signaturePerson>

	<signaturePerson>
		<signatureReportingPerson>MPM Asset Management Investors BV2014 LLC </signatureReportingPerson>

					<signatureDetails>
				<signature>/s/ Ansbert Gadicke</signature>
				<title>Managing Director of MPM BioVentures 2014 LLC, the manager of MPM Asset Management Investors BV2014 LLC</title>
				<date>01/31/2025</date>
			</signatureDetails>

	</signaturePerson>

	<signaturePerson>
		<signatureReportingPerson>UBS Oncology Impact Fund L.P. </signatureReportingPerson>

					<signatureDetails>
				<signature>/s/ Ansbert Gadicke</signature>
				<title>Managing Partner of MPM BioImpact LLC, the GP of Oncology Impact Fund (Cayman) Management L.P., the GP of UBS Oncology Impact Fund L.P.</title>
				<date>01/31/2025</date>
			</signatureDetails>

	</signaturePerson>

	<signaturePerson>
		<signatureReportingPerson>MPM BioVentures 2014 GP LLC </signatureReportingPerson>

					<signatureDetails>
				<signature>/s/ Ansbert Gadicke</signature>
				<title>Managing Director of MPM BioVentures 2014 LLC, the Managing Member of MPM BioVentures 2014 GP LLC</title>
				<date>01/31/2025</date>
			</signatureDetails>

	</signaturePerson>

	<signaturePerson>
		<signatureReportingPerson>MPM BioVentures 2014 LLC </signatureReportingPerson>

					<signatureDetails>
				<signature>/s/ Ansbert Gadicke</signature>
				<title>Managing Director</title>
				<date>01/31/2025</date>
			</signatureDetails>

	</signaturePerson>

	<signaturePerson>
		<signatureReportingPerson>Oncology Impact Fund (Cayman) Management L.P. </signatureReportingPerson>

					<signatureDetails>
				<signature>/s/ Ansbert Gadicke</signature>
				<title>Managing Partner of MPM BioImpact LLC, the General Partner of Oncology Impact Fund (Cayman) Management L.P.</title>
				<date>01/31/2025</date>
			</signatureDetails>

	</signaturePerson>

	<signaturePerson>
		<signatureReportingPerson>MPM BioImpact LLC </signatureReportingPerson>

					<signatureDetails>
				<signature>/s/ Ansbert Gadicke</signature>
				<title>Managing Partner</title>
				<date>01/31/2025</date>
			</signatureDetails>

	</signaturePerson>

	<signaturePerson>
		<signatureReportingPerson>ANSBERT GADICKE</signatureReportingPerson>

					<signatureDetails>
				<signature>/s/ Ansbert Gadicke</signature>
				<title>Ansbert Gadicke</title>
				<date>01/31/2025</date>
			</signatureDetails>

	</signaturePerson>

	<signaturePerson>
		<signatureReportingPerson>LUKE EVNIN</signatureReportingPerson>

					<signatureDetails>
				<signature>/s/ Luke Evnin</signature>
				<title>Luke Evnin</title>
				<date>01/31/2025</date>
			</signatureDetails>

	</signaturePerson>

	<signaturePerson>
		<signatureReportingPerson>Todd Foley</signatureReportingPerson>

					<signatureDetails>
				<signature>/s/ Todd Foley</signature>
				<title>Todd Foley</title>
				<date>01/31/2025</date>
			</signatureDetails>

	</signaturePerson>



</signatureInfo>
</formData>



</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1
<SEQUENCE>2
<FILENAME>ex-1-01312025_090159.htm
<DESCRIPTION>JOINT FILING STATEMENT
<TEXT>
<!DOCTYPE html PUBLIC "-//IETF//DTD HTML//EN">
<html><head><title>ex-1-01312025_090159.htm</title></head><body style="margin-top:0;font-family:Times New Roman; font-size:10pt; color:#000000">
<p style="margin:0px; font-size:11pt" align="center"><b>Joint Filing Statement</b></p>
<p style="margin:0px"><br></p>
<p style="margin:0px; padding-left:48px; padding-right:-6px; text-indent:52.8px; font-size:11pt" align="justify">I, the undersigned, hereby express my agreement that the attached Schedule&nbsp;13D (and any amendments thereto) relating to the beneficial ownership by the undersigned of the equity securities of Repare Therapeutics Inc. is filed on behalf of each of the undersigned.</p>
<p style="margin:0px"><br></p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">Date: &nbsp;January 31, 2025</p>
<p style="margin:0px"><br></p>
<p style="margin-top:0px; margin-bottom:16px; padding-left:48px; padding-right:67.2px; font-size:11pt"><b>MPM BioVentures 2014, L.P.</b></p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">By: &nbsp;MPM BioVentures 2014 GP LLC, </p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;its General Partner</p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">By: &nbsp;MPM BioVentures 2014 LLC, </p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Its Managing Member</p>
<p style="margin:0px"><br></p>
<p style="margin:0px"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; text-indent:48px; width:114px; font-size:11pt; float:left">By:</p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; text-indent:-2px; font-size:11pt"><u>/s/ Ansbert Gadicke</u></p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt; clear:left">Name: &nbsp;&nbsp;Ansbert Gadicke</p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">Title: &nbsp;&nbsp;&nbsp;&nbsp;Managing Director</p>
<p style="margin-top:0px; margin-bottom:16px"><br></p>
<p style="margin-top:0px; margin-bottom:16px; padding-left:48px; padding-right:67.2px; font-size:11pt"><b>MPM BioVentures 2014 (B), L.P.</b></p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">By: &nbsp;MPM BioVentures 2014 GP LLC, </p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;its General Partner</p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">By: &nbsp;MPM BioVentures 2014 LLC, </p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Its Managing Member</p>
<p style="margin:0px"><br></p>
<p style="margin:0px"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; text-indent:48px; width:114px; font-size:11pt; float:left">By:</p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; text-indent:-2px; font-size:11pt"><u>/s/ Ansbert Gadicke</u></p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt; clear:left">Name: &nbsp;&nbsp;Ansbert Gadicke</p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">Title: &nbsp;&nbsp;&nbsp;&nbsp;Managing Director</p>
<p style="margin:0px"><br></p>
<p style="margin-top:0px; margin-bottom:16px; padding-left:48px; padding-right:67.2px; font-size:11pt"><b>MPM Asset Management Investors BV 2014 LLC</b></p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">By: MPM BioVentures 2014 LLC</p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Its: Manager</p>
<p style="margin:0px"><br></p>
<p style="margin:0px"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; text-indent:48px; width:114px; font-size:11pt; float:left">By:</p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; text-indent:-2px; font-size:11pt"><u>/s/ Ansbert Gadicke</u></p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt; clear:left">Name: &nbsp;&nbsp;Ansbert Gadicke</p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">Title: &nbsp;&nbsp;&nbsp;&nbsp;Managing Director</p>
<p style="margin:0px"><br></p>
<p style="margin-top:0px; margin-bottom:16px"><br></p>
<p style="margin-top:0px; margin-bottom:16px"><br></p>
<p style="margin-top:0px; margin-bottom:16px"><br></p>
<p style="margin-top:0px; margin-bottom:16px"><br></p>
<p style="margin-top:0px; margin-bottom:16px"><br><br></p>
<hr style="margin-bottom: 9.6px; padding-top: 9.6px;" noshade size="1"><p style="margin-top:0px; margin-bottom:16px; padding-left:48px; padding-right:67.2px; font-size:11pt; page-break-before:always"><b>MPM BioVentures 2014 GP, LLC</b></p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">By: &nbsp;MPM BioVentures 2014 LLC, </p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Its Managing Member</p>
<p style="margin:0px"><br></p>
<p style="margin:0px"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; text-indent:48px; width:114px; font-size:11pt; float:left">By:</p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; text-indent:-2px; font-size:11pt"><u>/s/ Ansbert Gadicke</u></p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt; clear:left">Name: &nbsp;&nbsp;Ansbert Gadicke</p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">Title: &nbsp;&nbsp;&nbsp;&nbsp;Managing Director</p>
<p style="margin-top:0px; margin-bottom:16px"><br></p>
<p style="margin-top:0px; margin-bottom:16px; padding-left:48px; padding-right:67.2px; font-size:11pt"><b>MPM BioVentures 2014 LLC</b></p>
<p style="margin:0px"><br></p>
<p style="margin:0px"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; text-indent:48px; width:114px; font-size:11pt; float:left">By:</p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; text-indent:-2px; font-size:11pt"><u>/s/ Ansbert Gadicke</u></p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt; clear:left">Name: &nbsp;&nbsp;Ansbert Gadicke</p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">Title: &nbsp;&nbsp;&nbsp;&nbsp;Managing Director</p>
<p style="margin:0px"><br></p>
<p style="margin-top:0px; margin-bottom:16px; padding-left:48px; padding-right:67.2px; font-size:11pt"><b>UBS Oncology Impact Fund, L.P.</b></p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">By: &nbsp;Oncology Impact Fund (Cayman) Management L.P., </p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;its General Partner</p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">By: &nbsp;MPM BioImpact LLC, </p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Its General Partner</p>
<p style="margin:0px"><br></p>
<p style="margin:0px"><br></p>
<p style="margin:0px"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; text-indent:48px; width:114px; font-size:11pt; float:left">By:</p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; text-indent:-2px; font-size:11pt"><u>/s/ Ansbert Gadicke</u></p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt; clear:left">Name: &nbsp;&nbsp;Ansbert Gadicke</p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">Title: &nbsp;&nbsp;&nbsp;&nbsp;Managing Partner</p>
<p style="margin:0px"><br></p>
<p style="margin-top:0px; margin-bottom:16px; padding-left:48px; padding-right:67.2px; font-size:11pt"><b>Oncology Impact Fund (Cayman) Management L.P.</b></p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">By: &nbsp;MPM BioImpact LLC, </p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Its General Partner</p>
<p style="margin:0px"><br></p>
<p style="margin:0px"><br></p>
<p style="margin:0px"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; text-indent:48px; width:114px; font-size:11pt; float:left">By:</p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; text-indent:-2px; font-size:11pt"><u>/s/ Ansbert Gadicke</u></p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt; clear:left">Name: &nbsp;&nbsp;Ansbert Gadicke</p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">Title: &nbsp;&nbsp;&nbsp;&nbsp;Managing Partner</p>
<p style="margin:0px"><br></p>
<p style="margin-top:0px; margin-bottom:16px; padding-left:48px; padding-right:67.2px; font-family:Times New Roman Bold,Times New Roman; font-size:11pt"><b>MPM BioImpact LLC</b></p>
<p style="margin:0px"><br></p>
<p style="margin:0px"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; text-indent:48px; width:114px; font-size:11pt; float:left">By:</p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; text-indent:-2px; font-size:11pt"><u>/s/ Ansbert Gadicke</u></p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt; clear:left">Name: &nbsp;&nbsp;Ansbert Gadicke</p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">Title: &nbsp;&nbsp;&nbsp;&nbsp;Managing Partner</p>
<p style="margin:0px"><br></p>
<p style="margin:0px"><br></p>
<p style="margin:0px"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; text-indent:48px; width:114px; font-size:11pt; float:left">By:</p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; text-indent:-2px; font-size:11pt"><u>/s/ Todd Foley</u></p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt; clear:left">Name: &nbsp;&nbsp;Todd Foley</p>
<p style="margin:0px"><br></p>
<p style="margin:0px"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; text-indent:48px; width:114px; font-size:11pt; float:left">By:</p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; text-indent:-2px; font-size:11pt"><u>/s/ Luke Evnin</u></p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt; clear:left">Name: &nbsp;&nbsp;Luke Evnin</p>
<p style="margin:0px"><br></p>
<p style="margin:0px"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; text-indent:48px; width:114px; font-size:11pt; float:left">By:</p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; text-indent:-2px; font-size:11pt"><u>/s/ Ansbert Gadicke</u></p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt; clear:left">Name: &nbsp;&nbsp;Ansbert Gadicke</p>
<p style="margin-top:0px; margin-bottom:16px"><br></p>
<p style="margin:0px"><br></p>
<p style="margin:0px"><br></p>
<p style="margin:0px"><br><br></p>
</body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
